Mathematical modelling and quantitative methods

Food and Chemical Toxicology

Volumn 40, Issue 2-3, 2002, Pages 283-326

  Edler, L ^a   Poirier, K ^b   Dourson, M ^b   Kleiner, J ^c   Mileson, B ^d   Nordmann, H ^e   Renwick, A ^f   Slob, W ^g   Walton, K ^f   Wurtzen G ^h  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Toxicology Excellence for Risk Assessment   (United States)

^c International Life Sciences Institute of Europe   (Belgium)

^d Technology Sciences Group Inc   (United States)

^e Ajinomoto Switzerland AG   (Switzerland)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^h Coca Cola Nordic and Baltics ^*  (Denmark)

Author keywords

Benchmark; Categorical regression; Hazard characterisation; Mathematical modelling; Probabilistic methods; Risk assessment; Toxicokinetic models

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; FOOD ADDITIVE; TRACE ELEMENT;

DECISION MAKING; DIET; ETHNIC DIFFERENCE; EUROPE; FOOD SAFETY; HAZARD ASSESSMENT; HUMAN; MATHEMATICAL MODEL; MEDICAL SOCIETY; METHODOLOGY; NONHUMAN; PROBABILITY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; TOXICOKINETICS;

ANIMALS; DECISION MAKING; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN UNION; HAZARDOUS SUBSTANCES; HUMANS; MODELS, ANIMAL; MODELS, THEORETICAL; RISK ASSESSMENT; STRUCTURE-ACTIVITY RELATIONSHIP; THRESHOLD LIMIT VALUES;

ANIMALIA;

EID: 0036119438     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(01)00116-8     Document Type: Review

References (110)

1. Estimation of potential health effects from acute exposure to hydrogen fluoride using a "benchmark dose" approach
2. Physiological modeling of organic compounds
3. Noncancer risk assessment: A probabilistic alternative to current practice
4. Probabilistic noncancer risk estimation
5. Hazard identification by methods of animal-based toxicology
6. Benchmark dose workshop: Criteria for use of a benchmark dose to estimate a reference dose
7. Family approach for estimating reference concentrations/doses for series of related organic chemicals
8. Improvements in quantitative noncancer risk assessment
9. Use of mechanistic information in risk assessment for toxic chemicals
10. Physiological parameter values for physiologically based pharmacokinetic models
11. Uncertainty factors and interindividual variation
12. Does the animal-to-human uncertainty factor incorporate interspecies differences in surface area?
13. Estimation of a toxic hazard - A decision tree approach
14. A new method for determining allowable daily intakes
15. Calculation of benchmark doses from continuous data
16. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats
17. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives
18. Ranking chemicals based on chronic toxicity data
19. Acute toxicity and eye irritation
20. Uncertainty factors for chemical risk assessment: Human variability in the in vivo pharmacokinetics of CYP1A2 substrates
21. Boron tolerable intake: Re-evaluation of toxicokinetics for data-derived uncertainty factors
22. Evolution of science-based uncertainty factors in noncancer risk assessment
23. Novel approaches for the estimation of acceptable daily intake
24. On reference dose (RfD) and its underlying toxicity data base
25. Regulatory history and experimental support of uncertainty (safety) factors
26. Categorial regression of toxicity data: A case study using Aldicarb
27. Hazard characterisation of chemicals in food and diet: Dose-response, mechanisms, and extrapolation issues
28. Methods of in vitro toxicology
29. Reproductive and developmental risks from ethylene oxide: A probabilistic characterization of possible regulatory thresholds
30. Draft revised toxicological principles for the safety assessment of direct food additives and color additives used in food
31. Food additives: Threshold of regulation for substances used in food-contact materials
32. Physiologically based pharmacokinetic modelling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse
33. Physiologically based pharmacokinetic modeling: Principles and applications
34. A carcinogenic potency database of the standardized results of animal bioassays
35. Categorical regression analysis of acute exposure to tetrachloroethylene
36. Non-cancer risk assessment for nickel compounds: Issues associated with dose-response modeling of inhalation and oral exposures
37. FDA's priority-based assessment of food additives. III. Specific toxicity parameters
38. Distributions of individual susceptibility among humans for toxic effects. How much protection does the traditional tenfold factor provide for what fraction of which kinds of chemicals and effects?
39. Human interindividual variability in parameters related to health risks
40. Human variability in susceptibility to toxic chemicals: A preliminary analysis of pharmacokinetic data from normal volunteers
41. Quantitative extrapolation of toxicological findings
42. A statistical model for species extrapolation using categorial response data
43. Modeling the severity of toxic effects. 1991
44. A simulation study of the influence of study design on the estimation of benchmark doses for developmental toxicity
45. Issues in qualitative and quantitative risk analysis for developmental toxicology
46. Conversion factors estimating indicative chronic NOAELs from short-term toxicity data
47. Health risk assessment of drinking water contaminants in Canada: The applicability of mixture risk assessment methods
48. Threshold of toxicological concern for chemical substances present in the diet: A practical tool for assessing the need for toxicity testing
49. Assessment of intake from the diet
50. Workshop on the scientific evaluation of the safety factor for the acceptable daily intake (ADI): Editorial summary
51. 100-Fold margin of safety
52. A new approach to deriving community exposure guidelines from "no-observed-adverse-effect levels"
53. Quantitative risk assessment and the limitations of the linearized multistage model
54. Estimation of a chromium inhalation reference concentration using the benchmark dose method: A case study
55. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans
56. The application of physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling to understanding the mechanism of action of hazardous substances
57. Assessment of effect levels of chemicals from quantitative structure-activity relationship (QSAR) models. I. Chronic lowest-observed-adverse-effect level (LOAEL)
58. Risk assessment of chemical mixtures: Biologic and toxicological issues
59. Correlation of structural class with no-observed-effect levels: A proposal for establishing a threshold of concern
60. A procedure for the safety evaluation of flavouring substances. Joint FAO/WHO Expert Committee on Food Additives
61. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients
62. Physiologically based pharmacokinetic modeling of a homologous series of barbiturates in the rat: A sensitivity analysis
63. Guidance document for the development of OECD Guidelines for testing of chemicals
64. Genetic polymorphisms in ethanol metabolism: Issues and goals for physiologically based pharmacologic modeling
65. Comparing alternative approaches to establishing regulatory levels for reproductive toxicants: DBCP as a case study
66. Developmental toxicity of butyl benzyl phtalate in the rat using a multiple dose study design
67. Risk assessment of deoxynivalenol in food: Concentration limits, exposure and effects
68. A physiologically-based pharmacokinetic model assessment of methyl t-butyl ether in groundwater for a bathing and showering determination
69. Safety factors and establishment of acceptable daily intakes
70. Data-derived safety factors for the evaluation of food additives and environmental contaminants
71. Toxicokinetics in infants and children in relation to the ADI and TDI
72. Pathway-related factors. The potential for human data to improve the scientific basis of risk assessment
73. An analysis of the need for an additional uncertainty factor for infants and children
74. Human variability and noncancer risk assessment - An analysis of the default uncertainty factor
75. Analysis of the adequacy of safety factors
76. Establishing data-derived adjustment factors from published pharmaceutical clinical trial data
77. Interval censoring and marginal analysis in ordinal regression
78. Thresholds in toxicology and risk assessment
79. A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: General framework
80. Physiologically-based pharmacokinetic model for trichloroethylene considering enterohepatic recirculation of major metabolites
81. Health risk above the reference dose for multiple chemicals
82. The contribution of epidemiology
83. Assessment factors for human health risk assessment: A discussion paper
84. Categorical default factors for interspecies differences in the major routes of xenobiotic elimination
85. Uncertainty factors for chemical risk assessment: Interspecies differences in the in vivo pharmacokinetics and metabolism of CYP1A2 substrates
86. Erythrosine in Toxicological Evaluation of Certain Food Additives and Contaminants
87. Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling